GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InventisBio Co Ltd (SHSE:688382) » Definitions » EV-to-EBITDA

InventisBio Co (SHSE:688382) EV-to-EBITDA : -11.90 (As of Jun. 05, 2024)


View and export this data going back to 2022. Start your Free Trial

What is InventisBio Co EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, InventisBio Co's enterprise value is ¥2,994.2 Mil. InventisBio Co's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was ¥-251.6 Mil. Therefore, InventisBio Co's EV-to-EBITDA for today is -11.90.

The historical rank and industry rank for InventisBio Co's EV-to-EBITDA or its related term are showing as below:

SHSE:688382' s EV-to-EBITDA Range Over the Past 10 Years
Min: -22.9   Med: -15.79   Max: -11.59
Current: -12.2

During the past 6 years, the highest EV-to-EBITDA of InventisBio Co was -11.59. The lowest was -22.90. And the median was -15.79.

SHSE:688382's EV-to-EBITDA is ranked worse than
100% of 451 companies
in the Biotechnology industry
Industry Median: 9.15 vs SHSE:688382: -12.20

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-06-05), InventisBio Co's stock price is ¥8.36. InventisBio Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was ¥-0.430. Therefore, InventisBio Co's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


InventisBio Co EV-to-EBITDA Historical Data

The historical data trend for InventisBio Co's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InventisBio Co EV-to-EBITDA Chart

InventisBio Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial - - - -11.63 -25.54

InventisBio Co Quarterly Data
Dec18 Dec19 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -15.03 -13.79 -17.51 -25.54 -15.77

Competitive Comparison of InventisBio Co's EV-to-EBITDA

For the Biotechnology subindustry, InventisBio Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


InventisBio Co's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, InventisBio Co's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where InventisBio Co's EV-to-EBITDA falls into.



InventisBio Co EV-to-EBITDA Calculation

InventisBio Co's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=2994.197/-251.618
=-11.90

InventisBio Co's current Enterprise Value is ¥2,994.2 Mil.
InventisBio Co's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-251.6 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


InventisBio Co  (SHSE:688382) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

InventisBio Co's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=8.36/-0.430
=At Loss

InventisBio Co's share price for today is ¥8.36.
InventisBio Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-0.430.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


InventisBio Co EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of InventisBio Co's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


InventisBio Co (SHSE:688382) Business Description

Traded in Other Exchanges
N/A
Address
No. 4, Lane 67, Li Bing Road, Room 210, Pilot Free Trade Zone, Shanghai, CHN, 201203
InventisBio Co Ltd is an innovative drug research and development enterprise based in China with a global perspective, focusing on major diseases such as tumors and metabolic diseases. It has independently developed a series of innovative targeted drugs with patent protection, covering non-small cell lung cancer, breast cancer, colorectal cancer and other solid tumors, as well as hyperuricemia and metabolic diseases such as gout.

InventisBio Co (SHSE:688382) Headlines

No Headlines